This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Idogen Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Idogen.

Anahtar bilgiler

50.6%

Kazanç büyüme oranı

76.1%

EPS büyüme oranı

Biotechs kazanç büyümesi	45.6%
Gelir büyüme oranı	-122.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	10 May 2023

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

OM:IDOGEN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (SEK Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	N/A	-12	-12	-12	2
12/31/2024	N/A	-12	-11	-12	2
12/31/2023	N/A	-37	-39	-38	2
3/31/2023	1	-44	-42	-40	N/A
12/31/2022	0	-48	-52	-51	N/A
9/30/2022	3	-50	-55	-53	N/A
6/30/2022	11	-41	-54	-52	N/A
3/31/2022	12	-39	-48	-48	N/A
12/31/2021	14	-39	-41	-40	N/A
9/30/2021	13	-33	-36	-36	N/A
6/30/2021	7	-33	-34	-33	N/A
3/31/2021	8	-31	-37	-36	N/A
12/31/2020	8	-27	-28	-28	N/A
9/30/2020	7	-27	-25	-25	N/A
6/30/2020	6	-29	-27	-27	N/A
3/31/2020	5	-32	-25	-25	N/A
12/31/2019	4	-33	-36	-35	N/A
9/30/2019	7	-29	-29	-28	N/A
6/30/2019	6	-30	-28	-26	N/A
3/31/2019	5	-27	-30	-27	N/A
12/31/2018	4	-28	-14	-10	N/A
9/30/2018	N/A	-30	-24	-18	N/A
6/30/2018	N/A	-29	-24	-19	N/A
3/31/2018	N/A	-25	-18	-12	N/A
12/31/2017	N/A	-21	-24	-20	N/A
9/30/2017	0	-18	-17	-15	N/A
6/30/2017	0	-14	-11	-9	N/A
3/31/2017	0	-13	-12	-12	N/A
12/31/2016	0	-13	N/A	-11	N/A
9/30/2016	0	-12	N/A	-12	N/A
6/30/2016	0	-12	N/A	-12	N/A
3/31/2016	0	-10	N/A	-10	N/A
12/31/2015	0	-10	N/A	-9	N/A
9/30/2015	0	-8	N/A	-8	N/A
6/30/2015	1	-6	N/A	-5	N/A
3/31/2015	0	-4	N/A	-3	N/A
12/31/2014	0	-2	N/A	-2	N/A
12/31/2013	0	0	N/A	0	N/A
12/31/2012	0	0	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IDOGEN is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: IDOGEN is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: IDOGEN is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: IDOGEN is forecast to have no revenue next year.

Yüksek Büyüme Geliri: IDOGEN is forecast to have no revenue next year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if IDOGEN's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Idogen Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Nasdaq Stockholm Decides to Delist the Shares of Idogen from Nasdaq First North Growth Market

Idogen AB (publ) to Report First Half, 2023 Results on Aug 23, 2023

Idogen AB (publ) Appoints Jan Holgersson to Its Board of Directors

High number of new and inexperienced directors

Idogen AB Announces Board Changes

Idogen AB (Publ) Announces First Patient Enters Idogen's Hemophilia Study Under the Ido 8 Program

Idogen AB (publ) Announces Board Changes

Idogen Receives Approval from the Regional Ethics Committee to Conduct Clinical Phase I/IIa Study

Idogen Appoints Christina Herder as Acting CEO

Redeye Updates Their Analysis of Idogen as Company Approaches Clinical Phase

Redeye Updates Their Analysis of Idogen as Company Approaches Clinical Phase

Idogen AB (Publ) Announces CEO Executive Changes

Idogen AB (publ) is Preparing to Start Clinical Phase 1/2A Study with IDO 8 in Norway

No independent directors

Idogen AB (publ) Announces Study Approval in Norway and Sweden

Idogen Strengthens the Organization Before the Clinical Development Phase

Idogen AB (Publ) Receives Approval from the Norwegian Medicines Agency, Noma, for the Start of Clinical Phase 1/2A Study with IDO 8

Idogen Receives Approval from the Swedish Medical Products Agency for the Clinical Phase I/IIa Study with IDO 8

Idogen AB (publ) has completed a Composite Units Offering in the amount of SEK 50.425465 million.

Idogen AB (Publ) Submits Application to Norwegian Medicines Agency to Begin Clinical Phase 1/2A Study of the Advanced Cell Therapy Treatment IDO 8 in Norway

Idogen Submits Clinical Trial Application

Idogen AB Submits an Application to the Swedish Medical Products Agency to Initiate A Clinical Phase 1/2A Study of the Cell Therapy Treatment IDO 8

Idogen AB (publ) Completes the Optimization of the GMP Manufacturing Process for the First Clinical Study with Its Tolerogenic Cell Therapy IDO 8

CEO & MD recently bought kr144k worth of stock

Idogen AB Receives Confirmation the European Patent Office Intends to Grant A Patent Application

New 90-day low: kr2.99

Idogen AB (publ) Announces Executive Changes

New 90-day low: kr3.08

New 90-day low: kr3.27

New 90-day low: kr3.63

New 90-day low: kr3.98

New 90-day low: kr5.06

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin